NEXT is a closed-end fund of funds subscribed by institutional investors and dedicated to Venture Capital. On 11 September 2004, final closing was perfected with subscriptions from the most important Italian Banks, Foundations and Public Bodies. One of NEXT’s main characteristic is to be the first a...

Genextra is a private biopharmaceutical company committed to the development of innovative therapeutics primarily for the cure of age-related and metabolic diseases and of cancer. Genextra develops its programs through four operative subsidiaries: Congenia, DAC, Tethis and Intercept Pharmaceutica...

MAC is a Multilateral Trading Facility (MTF) whose regulatory framework is based on London’s Alternative Investment Market (AIM), adapting some of the elements key to its success to the Italian economic and business environment. MAC admission process is extremely streamlined; unlike AIM, however, MA...

Quantica SGR is an Asset Management Company specialized in closed-end funds for venture capital activities, investing in high-tech spin-offs and start-up stemming from scientific research, as well as early-stage financing. Our mission is to be the Venture Capital of Research: Principia Fund is the f...

SG Cowen is active in biotech under the SG Cowen brand name. Main activities inclede M&A advisory and equity offerings (IPOs, dual listings, convertible bonds, follow-ons). From a private equity perspective, SG manages different funds specialised in new technologies.

TT Venture is the first Italian closed-end fund dedicated to Technology Transfer, a meaningful novelty in the Italian Venture Capital scenario, which is still...

Z-Cube is a corporate company of Zambon Company S.p.A. acting as an international technology scout & broker focused on Drug Delivery Technologies (DDTs) exploitation, Our Mission is to identify and support the validation of early stage Drug Delivery Technologies. Z-Cube has two main objectives: a...